Venetoclax, a BH3-mimetic FDA-approved drug for 17p-deleted refractory chronic lymphocytic leukemia, antagonizes BCL-2 and induces apoptosis [72]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.